Daniel A. Pollyea, MD, MS (IMAGE)

University of Colorado Anschutz

Daniel A. Pollyea, MD, MS

Caption

Daniel A. Pollyea, MD, MS and colleagues report clinical trial results leading to FDA approval of ivosidenib against IDH1+ AML.

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.